[email protected]: Australia's advantage 

[email protected] will provide capability and innovative pathways for emerging and growing med-tech start-ups through specialist infrastructure and biomedical manufacturing capabilities, facilitating the pipeline of new start-ups.

How [email protected] will benefit the health of Australia's community and industry 

• Developing national capabilities in the MTP sector 
• Contributing to national innovation and capacity building of innovative business, manufacturing and industry
• Advancing research commercialisation and export opportunities
• Increasing ‘sovereign capability’ and manufacturing capability against pandemics
• Promoting engagement between the research sector, hospitals and industry
• Retaining MedTech start-up companies in Australia 
• Creating a pipeline of start-ups transitioning from TRI to [email protected] 
• Enhancing the reputation of Queensland and Australian innovation through research and commercialisation success - Eg. Gardasil HPV vaccine development as the foundation for TRI
• Providing practical cGMP training to early-career researchers and SMEs and building Australia's skilled workforce
• Creating jobs (direct and indirect) and spin-off benefits across multiple allied industries, including over 1400 construction jobs and 200 associated jobs every year for the first five years of its operation
• Increasing productivity through proximity to and collaboration with the established research and clinical expertise on the precint
• Attracting and retaining the best scientists, who can engage in leading research and development
• Increasing opportunities for Queenslanders and Australians to participate in clinical trials. 

Register an Expression of Interest here: https://www.surveymonkey.com/r/7D8ZDJF.